|
|
Vaccine Detail
|
Class I HLA-A*0201-restricted gp100209-2M peptide vaccine |
| Vaccine Information |
- Vaccine Name: Class I HLA-A*0201-restricted gp100209-2M peptide vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007593
- Type: peptide
- Status: Research
- Preparation: Seventy HLA-A*0201+ stage IIb–IV melanoma patients were vaccinated with class I HLA-A*0201-restricted gp100209-2M peptide and stratiļ¬ed for HLA-DP4 restriction. HLA-DP4+ patients were also vaccinated with class II HLA-DP4-restricted MAGE-3243-258 peptide. Patients from both groups were randomized to receive 2 doses of leuprolide or not (Vence et al., 2013).
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: Small increase in TREC-enriched CD8+CD45RA+RO-CD27+CD103+ but not in TREC-enriched CD4+CD45RA+ROCD31+ t-cell population. Igf-1 levels were not changed, moderate increase in IL-7 levels in th sera of all patients 6 weeks after vaccination. Increased expression of CD127 (IL-7 receptor-a) at week 24, compared with baseline, was only seen in the CD8+CD45RA+ROCD27+CD103+ T-cell population (Vence et al., 2013).
|
| References |
Vence et al., 2013: Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P. Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. Journal of immunotherapy (Hagerstown, Md. : 1997). 2013; 36(4); 276-286. [PubMed: 23603862].
|
|
